Critical issues of PTH assays in CKD

Bone

Volumn 44, Issue 4, 2009, Pages 666-670

  Komaba, Hirotaka ^a   Goto, Shunsuke ^a   Fukagawa, Masafumi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C PTH fragments; N PTH; PTH assay; PTH(1 84); PTH(7 84)

Indexed keywords

22 OXACALCITRIOL; CINACALCET; PARATHYROID HORMONE; VITAMIN D DERIVATIVE;

ARTICLE; BONE DISEASE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; DIAGNOSTIC ACCURACY; HORMONE DETERMINATION; HUMAN; HYPERPARATHYROIDISM; INTERRATER RELIABILITY; MORTALITY; PARATHYROID CARCINOMA; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PATIENT MONITORING; RISK FACTOR; UREMIA;

BONE DISEASES; HEMATOLOGIC TESTS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PEPTIDE FRAGMENTS;

EID: 61749100106     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.12.016     Document Type: Article

References (74)

1. Keutman H.T., Sauer M.M., Hendy G.N., O'Riordan J.L., and Potts Jr. J.T. Complete amino acid sequence of human parathyroid hormone. Biochemistry 17 (1978) 5723-5729
2. Tregear G.W., Van Rietschoten J., Greene E., Keutmann H.T., Niall H.D., Reit B., et al. Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology 93 (1973) 1349-1353
3. Jüppner H., Abou-Samra A.B., Freeman M., Kong X.F., Schipani E., Richards J., et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254 (1991) 1024-1026
4. Divieti P., Inomata N., Chapin K., Singh R., Juppner H., and Bringhurst F.R. Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142 (2001) 916-925
5. Divieti P., Geller A.I., Suliman G., Jüppner H., and Bringhurst F.R. Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology 146 (2005) 1863-1870
6. Segre G.V., D'Amour P., Hultman A., and Potts Jr. J.T. Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. J. Clin. Invest. 67 (1981) 439-448
7. Segre G.V., Perkins A.S., Witters L.A., and Potts Jr. J.T. Metabolism of parathyroid hormone by isolated rat Kupffer's cells and hepatocytes. J. Clin. Invest. 67 (1981) 449-457
8. D'Amour P., and Brossard J.H. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr. Opin. Nephrol. Hypertens. 14 (2005) 330-336
9. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int. 70 Suppl 102 (2006) S29-S33
10. Drueke T.B. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J. Am. Soc. Nephrol. 11 (2000) 1141-1152
11. Silver J., Kilav R., and Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am. J. Physiol. Renal. Physiol. 283 (2002) F367-F376
12. Fukagawa M., Nakanishi S., and Kazama J.J. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int. 70 Suppl 102 (2006) S3-S7
13. Goto S., Komaba H., and Fukagawa M. Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention. NDT Plus 1 Suppl 3 (2008) iii2-iii8
14. Shigematsu T., Kazama J.J., Yamashita T., Fukumoto S., Hosoya T., Gejyo F., et al. Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 44 (2004) 250-256
15. Nakanishi S., Kazama J.J., Nii-Kono T., Omori K., Yamashita T., Fukumoto S., et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 67 (2005) 1171-1178
16. Fukagawa M., and Kazama J.J. With or without the kidney: the role of FGF23 in CKD. Nephrol. Dial. Transplant. 20 (2005) 1295-1298
17. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., and Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15 (2004) 2208-2218
18. Kalantar-Zadeh K., Kuwae N., Regidor D.L., Kovesdy C.P., Kilpatrick R.D., Shinaberger C.S., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 70 (2006) 771-780
19. Nakai S., Akiba T., Kazama J., Yokoyama K., Fukagawa M., Tominaga Y., et al. Effects of serum levels of calcium, phosphorous, and intact PTH on survival in chronic hemodialysis patients in Japan. Ther. Apher. Dial. 12 (2008) 49-54
20. National Kidney Foundation. K/DOQI Clinical Practice Guidelines. Am. J. Kidney Dis. 42 Suppl 3 (2003) S1-S202
21. Brossard J.H., Cloutier M., Roy L., Lepage R., Gascon-Barre M., and D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J. Clin. Endocrinol. Metab. 81 (1996) 3923-3929
22. Gao P., and D'Amour P. Evolution of the parathyroid hormone (PTH) assay-importance of circulating PTH immunoheterogeneity and of its regulation. Clin. Lab. 51 (2005) 21-29
23. D'Amour P. Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients. J. Endocrinol. Invest. 31 (2008) 459-462
24. Berson S.A., and Yalow R.S. Immunochemical heterogeneity of parathyroid hormone in plasma. Clin. Endocrinol. Metab. 28 (1968) 1037-1047
25. Nussbaum S.R., Zahradnik R.J., Lavigne J.R., Brennan G.L., Nozawa-Ung K., Kim L.Y., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin. Chem. 33 (1987) 1364-1367
26. Brossard J.H., Lepage R., Cardinal H., Roy L., Rousseau L., Dorais C., et al. Influence of glomerular filtration rate on intact parathyroid hormone levels in renal failure patients: role of non-(1-84) PTH detected by intact PTH assays. Clin. Chem. 46 (2000) 697-703
27. Divieti P., John M.R., Juppner H., and Bringhurst F.R. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143 (2002) 171-176
28. Langub M.C., Monier-Faugere M.C., Wang G., Williams J.P., Koszewski N.J., and Malluche H.H. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144 (2003) 1135-1138
29. John M.R., Goodman W.G., Gao P., Cantor T.L., Salusky I.B., and Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 84 (1999) 4287-4290
30. Gao P., Scheibel S., D'Amour P., John M.R., Rao S.D., Schmidt-Gayk H., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone (1-84): implication for improvement of accurate assessment of parathyroid function. J. Bone Miner. Res. 16 (2001) 605-614
31. Nakanishi S., Kazama J.J., Shigematsu T., Iwasaki Y., Cantor T.L., Kurosawa T., et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am. J. Kidney Dis. 38 Suppl 1 (2001) S172-S174
32. Inaba M., Nakatsuka K., Imanishi Y., Watanabe M., Mamiya Y., Ishimura E., et al. Technical and clinical characterization of the Bio-PTH(1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin. Chem. 50 (2004) 385-390
33. Souberbielle J.C., Boutten A., Carlier M.C., Chevenne D., Coumaros G., Lawson-Body E., et al. Intermethod variability in PTH measurement: Implication for the care of CKD patients. Kidney Int. 70 (2006) 345-350
34. Joly D., Drueke T.B., Alberti C., Houillier P., Lawson-Body E., Martin K.J., et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am. J. Kidney Dis. 51 (2008) 987-995
35. Twomey P.J., Whitlock T., and Pledger D.R. Differences between serum and plasma for intact parathyroid hormone measurement in patients with chronic renal failure in routine clinical practice. J. Clin. Pathol. 58 (2005) 1000-1001
36. Cavalier E., Delanaye P., Carlisi A., Krzesinski J.M., and Chapelle J.P. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int. 72 (2007) 370-372
37. Sherrard D.J., Hercz G., Pei Y., Maloney N.A., Greenwood C., Manuel A., et al. The spectrum of bone disease in endstage renal failure-an evolving disorder. Kidney Int. 43 (1993) 436-442
38. Hercz G., Pei Y., Greenwood C., Manuel A., Saiphoo C., Goodman W.G., et al. Aplastic osteodystrophy without aluminium: the role of 'suppressed' parathyroid function. Kidney Int. 44 (1993) 860-866
39. Wang M., Hercz G., Sherrard D.J., Maloney N.A., Segre G.V., and Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am. J. Kidney Dis. 26 (1995) 836-844
40. Monier-Faugere M.C., Geng Z.P., Mawad H., Friedler R.M., Gao P., Cantor T.L., et al. Improved assessment of bone turnover by the PTH-(1-84) large C-PTH fragments ratio in ESRD patients. Kidney Int. 60 (2001) 1460-1468
41. Coen G., Bonucci E., Ballanti P., Balducci A., Calabria S., Nicolai G.A., et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am. J. Kidney Dis. 40 (2002) 348-354
42. Lehmann G., Stein G., Huller M., Schemer R., Ramakrishnan K., and Goodman W.G. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 68 (2005) 1206-1214
43. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12 (2008) 514-525
44. Noordzij M., Korevaar J.C., Boeschoten E.W., Dekker F.W., Bos W.J., and Krediet R.T. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am. J. Kidney Dis. 46 (2005) 925-932
45. Melamed M.L., Eustace J.A., Plantinga L.C., Jaar B.G., Fink N.E., Parekh R.S., et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol. Dial. Transplant. 23 (2008) 1650-1658
46. D'Amour P., Räkel A., Brossard J.H., Rousseau L., Albert C., and Cantor T. Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1-84) ratios derived from three generations of PTH assays. J. Clin. Endocrinol. Metab. 91 (2006) 283-289
47. Kawata T., Imanishi Y., Kobayashi K., Onoda N., Takemoto Y., Tahara H., et al. Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells. J. Clin. Endocrinol. Metab. 90 (2005) 5774-5778
48. Kazama J.J., Omori K., Higuchi N., Takahashi N., Ito Y., Maruyama H., et al. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 19 (2004) 892-897
49. Martin K.J., Jüppner H., Sherrard D.J., Goodman W.G., Kaplan M.R., Nassar G., et al. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int. 68 (2005) 1236-1243
50. Tominaga Y., Uchida K., Haba T., Katayama A., Sato T., Hibi Y., et al. More than 1000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am. J. Kidney Dis. 38 4 Suppl 1 (2001) S168-S171
51. Lokey J., Pattou F., Mondragon-Sanchez A., Minuto M., Mullineris B., Wambergue F., et al. Intraoperative decay profile of intact (1-84) parathyroid hormone in surgery for renal hyperparathyroidism-a consecutive series of 80 patients. Surgery 128 (2000) 1029-1034
52. Yamashita H., Gao P., Cantor T., Noguchi S., Uchino S., Watanabe S., et al. Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 135 (2004) 149-156
53. Yamashita H., Cantor T., Uchino S., Watanabe S., Ogawa T., Moriyama T., et al. Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. World J. Surg. 29 (2005) 169-173
54. Matsuoka S., Tominaga Y., Sato T., Uno N., Goto N., Katayama A., et al. QuiCk-IntraOperative Bio-Intact PTH assay at parathyroidectomy for secondary hyperparathyroidism. World J. Surg. 31 (2007) 824-831
55. D'Amour P., Brossard J.H., Rousseau L., Roy L., Gao P., and Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin. Chem. 49 (2003) 2037-2044
56. Räkel A., Brossard J.H., Patenaude J.V., Albert C., Nassif E., Cantor T., et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin. Endocrinol. 62 (2005) 721-727
57. Rubin M.R., Silverberg S.J., D'Amour P., Brossard J.H., Rousseau L., Sliney Jr. J., et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. Clin. Chem. 53 (2007) 1470-1476
58. Arakawa T., D'Amour P., Rousseau L., Brossard J.H., Sakai M., Kasumoto H., et al. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin. J. Am. Soc. Nephrol. 1 (2006) 525-531
59. Tanaka M., Itoh K., Matsushita K., Matsushita K., Fujii H., and Fukagawa M. Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin. Nephrol. 64 (2005) 69-72
60. Komaba H., Takeda Y., Abe T., Komaba K., Otsuki N., Nibu K., et al. Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. Nephrol. Dial. Transplant. 23 (2008) 1760-1762
61. Komaba H., Takeda Y., Shin J., Tanaka R., Kakuta T., Tominaga Y., et al. Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review. NDT Plus 1 Suppl 3 (2008) iii54-iii58
62. Mizumura Y., Mukaiyama Y., Osada H., Hida O., Nishimiya M., and Nakamura Y. The reversed ratio of 1-84 PTH (whole PTH)/intact PTH in a patient on hemodialysis associated with primary hyperparathyroidism. Clin. Nephrol. 69 (2008) 310-312
63. Boudou P., Ibrahim F., Cormier C., Sarfati E., and Souberbielle J.C. Unexpected serum parathyroid hormone profiles in some patients with primary hyperparathyroidism. Clin. Chem. 52 (2006) 757-760
64. Tanaka M., Komaba H., Itoh K., Matsushita K., Matshushita K., Hamada Y., et al. The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. NDT Plus 1 Suppl 3 (2008) iii59-iii62
65. Fukagawa M., Kazama J.J., and Shigematsu T. Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases. Am. J. Kidney Dis. 38 (2001) S152-S155
66. Slatopolsky E., Finch J., Clay P., Martin D., Sicard G., Singer G., et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 58 (2000) 753-761
67. Nii-Kono T., Iwasaki Y., Uchida M., Fujieda A., Hosokawa A., Motojima M., et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int. 71 (2007) 738-743
68. Iwasaki Y., Yamato H., Nii-Kono T., Fujieda A., Uchida M., Hosokawa A., et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol. Dial. Transplant. 21 (2006) 2768-2774
69. Yano S., Yamaguchi T., Kanazawa I., Ogawa N., Hayashi K., Yamauchi M., et al. The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. Nephrol. Dial. Transplant. 22 (2007) 3160-3165
70. Picton M.L., Moore P.R., Mawer E.B., Houghton D., Freemont A.J., Hutchison A.J., et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 58 (2000) 1440-1449
71. Iwasaki-Ishizuka Y., Yamato H., Nii-Kono T., Kurokawa K., and Fukagawa M. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol. Dial. Transplant. 20 (2005) 1904-1911
72. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
73. Kazama J.J., Shigematsu T., Yano K., Tsuda E., Miura M., Iwasaki Y., et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am. J. Kidney Dis. 39 (2002) 525-532
74. Lund R.J., Davies M.R., Brown A.J., and Hruska K.A. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J. Am. Soc. Nephrol. 15 (2004) 359-369